1
Clinical Trials associated with Insulin Aspart Biosimilar (Xentria)A Single-center, Single-dose, Double-blind, Randomized, Three-period, Three-treatment, Six-sequence, Crossover Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid® Using the Euglycemic Clamp Technique in Healthy Male Adult Volunteers
Single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®
100 Clinical Results associated with Insulin Aspart Biosimilar (Xentria)
100 Translational Medicine associated with Insulin Aspart Biosimilar (Xentria)
100 Patents (Medical) associated with Insulin Aspart Biosimilar (Xentria)
100 Deals associated with Insulin Aspart Biosimilar (Xentria)